These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 28243125)

  • 1. Carfilzomib boosted combination therapy for relapsed multiple myeloma.
    Steiner RE; Manasanch EE
    Onco Targets Ther; 2017; 10():895-907. PubMed ID: 28243125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma.
    Franken B; van de Donk NW; Cloos JC; Zweegman S; Lokhorst HM
    Ther Adv Hematol; 2016 Dec; 7(6):330-344. PubMed ID: 27904737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple Myeloma.
    Hoy SM
    Target Oncol; 2016 Apr; 11(2):255-62. PubMed ID: 26972294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of the role of carfilzomib in the treatment of multiple myeloma.
    Ziogas DC; Terpos E; Kastritis E; Dimopoulos MA
    Expert Opin Pharmacother; 2017 Dec; 18(17):1883-1897. PubMed ID: 29134824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carfilzomib: in relapsed, or relapsed and refractory, multiple myeloma.
    McCormack PL
    Drugs; 2012 Oct; 72(15):2023-32. PubMed ID: 22994535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carfilzomib for relapsed and refractory multiple myeloma.
    Groen K; van de Donk N; Stege C; Zweegman S; Nijhof IS
    Cancer Manag Res; 2019; 11():2663-2675. PubMed ID: 31037034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emerging role of carfilzomib combination therapy in the management of multiple myeloma.
    Moreau P
    Expert Rev Hematol; 2014 Apr; 7(2):265-90. PubMed ID: 24521249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.
    McBride A; Klaus JO; Stockerl-Goldstein K
    Am J Health Syst Pharm; 2015 Mar; 72(5):353-60. PubMed ID: 25694410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
    Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
    Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
    Steele JM
    J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of carfilzomib in the treatment of multiple myeloma.
    Khan RZ; Badros A
    Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.
    Stewart AK
    Future Oncol; 2015; 11(15):2121-36. PubMed ID: 26125319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
    Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of carfilzomib in relapsed/refractory multiple myeloma.
    Yee AJ
    Ther Adv Hematol; 2021; 12():20406207211019612. PubMed ID: 34163580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
    Thompson JL
    Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma.
    Bhutani D; Zonder JA
    Blood Lymphat Cancer; 2017; 7():53-60. PubMed ID: 31360084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone.
    Manasanch EE; de Larrea CF; Zingone A; Steinberg SM; Kwok M; Tageja N; Bhutani M; Kazandjian D; Roschewski M; Wu P; Carter G; Zuchlinski D; Mulquin M; Lamping L; Costello R; Burton D; Gil LA; Figg WD; Maric I; Calvo KR; Yuan C; Stetler-Stevenson M; Korde N; Landgren O
    Leuk Lymphoma; 2017 Mar; 58(3):639-645. PubMed ID: 27687480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib.
    Nooka A; Gleason C; Casbourne D; Lonial S
    Biologics; 2013; 7():13-32. PubMed ID: 23386784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
    Dimopoulos M; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Yang H; Klippel Z; Zahlten-Kumeli A; Usmani SZ
    Lancet; 2020 Jul; 396(10245):186-197. PubMed ID: 32682484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
    Stewart AK; Rajkumar SV; Dimopoulos MA; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel DS; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak AJ; San-Miguel JF; Ludwig H; Wang M; Maisnar V; Minarik J; Bensinger WI; Mateos MV; Ben-Yehuda D; Kukreti V; Zojwalla N; Tonda ME; Yang X; Xing B; Moreau P; Palumbo A;
    N Engl J Med; 2015 Jan; 372(2):142-52. PubMed ID: 25482145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.